Gene expression profiling of liver cancer stem cells by RNA-sequencing

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Ho, David W Y ^a   Yang, Zhen Fan ^a,b   Yi, Kang ^c   Lam, Chi Tat ^a   Ng, Michael N P ^a   Yu, Wan Ching ^a   Lau, Joyce ^a   Wan, Timothy ^a   Wang, Xiaoqi ^a,d   Yan, Zhixiang ^c   Liu, Hang ^c   Zhang, Yong ^c   Fan, Sheung Tat ^a,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b ASTRAZENECA   (United Kingdom)

^c BGI SHENZHEN   (China)

^d THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; THY 1 ANTIGEN; GLYPICAN; GPC3 PROTEIN, HUMAN; PRIMER DNA; RNA; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STEM CELL; CELL SELECTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LIVER CELL CARCINOMA; LUNG CARCINOGENESIS; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG SCREENING; GENE SILENCING; GENETICS; IMMUNOLOGY; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, THY-1; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GLYPICANS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; RNA, NEOPLASM; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY;

EID: 84861010015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037159     Document Type: Article

References (55)

1. Thorgeirsson SS, Grisham JW, (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346.
2. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171.
3. Ma S, Jiao B, Liu X, Yi H, Kong D, et al. (2009) Approach to radiation therapy in hepatocellular carcinoma. Cancer Treat Rev.
4. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, et al. (2001) Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 234: 63-70.
5. Abou-Alfa GK, (2006) Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol 33: S79-83.
6. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, et al. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
7. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, et al. (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106: 16281-16286.
8. Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG, Brunner TB, (2009) Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 75: 1216-1225.
9. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, et al. (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13: 153-166.
10. Chang HW, Kim SY, Yi SL, Son SH, Song do Y, et al. (2006) Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck. Oral Oncol 42: 979-986.
11. Ng KT, Lee TK, Cheng Q, Wo JY, Sun CK, et al. (2010) Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1. Int J Cancer 127: 859-872.
12. Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, et al. (2010) Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer 9: 74.
13. Wang K, Liu J, Yan ZL, Li J, Shi LH, et al. (2010) Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 52: 164-173.
14. Wang Y, Li Y, Liu S, Shen W, Jiang B, et al. (2005) Study on the dynamic behavior of a DNA microarray. J Nanosci Nanotechnol 5: 1249-1255.
15. Casneuf T, Van de Peer Y, Huber W, (2007) In situ analysis of cross-hybridisation on microarrays and the inference of expression correlation. BMC Bioinformatics 8: 461.
16. Lin B, White JT, Lu W, Xie T, Utleg AG, et al. (2005) Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 65: 3081-3091.
17. Trapnell C, Pachter L, Salzberg SL, (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105-1111.
18. Storey JD, Tibshirani R, (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
19. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, et al. (2003) Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab 88: 2309-2317.
20. Feldman AL, Costouros NG, Wang E, Qian M, Marincola FM, et al. (2002) Advantages of mRNA amplification for microarray analysis. Biotechniques 33: 906-912, 914.
21. Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, et al. (2009) mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods 6: 377-382.
22. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799-816.
23. Mudge J, Miller NA, Khrebtukova I, Lindquist IE, May GD, et al. (2008) Genomic convergence analysis of schizophrenia: mRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum. PLoS One 3: e3625.
24. Tuch BB, Laborde RR, Xu X, Gu J, Chung CB, et al. (2010) Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. PLoS One 5: e9317.
25. Pettigrew CA, Brown MA, (2008) Pre-mRNA splicing aberrations and cancer. Front Biosci 13: 1090-1105.
26. Kim E, Goren A, Ast G, (2008) Alternative splicing and disease. RNA Biol 5: 17-19.
27. Miura K, Fujibuchi W, Sasaki I, (2010) Alternative pre-mRNA splicing in digestive tract malignancy. Cancer Sci.
28. Lin B, Madan A, Yoon JG, Fang X, Yan X, et al. (2010) Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. PLoS One 5: e10210.
29. Fu X, Fu N, Guo S, Yan Z, Xu Y, et al. (2009) Estimating accuracy of RNA-Seq and microarrays with proteomics. BMC Genomics 10: 161.
30. Masson NM, Currie IS, Terrace JD, Garden OJ, Parks RW, et al. (2006) Hepatic progenitor cells in human fetal liver express the oval cell marker Thy-1. Am J Physiol Gastrointest Liver Physiol 291: G45-54.
31. Suzuki M, Sugimoto K, Tanaka J, Tameda M, Inagaki Y, et al. (2010) Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res 30: 5055-5061.
32. Takahashi-Yanaga F, Kahn M, (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153-3162.
33. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, et al. (2009) Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 1155: 206-221.
34. Brigati C, Noonan DM, Albini A, Benelli R, (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19: 247-258.
35. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K, (2007) The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 31: 1465-1472.
36. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, et al. (2010) A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17: 348-361.
37. Davila JA, (2010) Diabetes and hepatocellular carcinoma: what role does diabetes have in the presence of other known risk factors? Am J Gastroenterol 105: 632-634.
38. Su WP, Chen YT, Lai WW, Lin CC, Yan JJ, et al. (2010) Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer.
39. Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, et al. (2008) Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene 27: 2810-2822.
40. Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, et al. (2010) ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids.
41. Liu N, Zhang LH, Du H, Hu Y, Zhang GG, et al. (2010) Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol 17: 2628-2639.
42. Carson-Walter EB, Hampton J, Shue E, Geynisman DM, Pillai PK, et al. (2005) Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis. Clin Cancer Res 11: 7643-7650.
43. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, et al. (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129: 899-906.
44. Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, et al. (2011) Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int 31: 120-131.
45. Grozdanov PN, Yovchev MI, Dabeva MD, (2006) The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest 86: 1272-1284.
46. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, et al. (2009) Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 100: 1403-1407.
47. Haupt LM, Murali S, Mun FK, Teplyuk N, Mei LF, et al. (2009) The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. J Cell Physiol 220: 780-791.
48. Sun CK, Chua MS, He J, So SK, (2011) Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2. Neoplasia 13: 735-747.
49. Cheng W, Tseng CJ, Lin TT, Cheng I, Pan HW, et al. (2008) Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 29: 1319-1326.
50. Farooq M, Hwang SY, Park MK, Kim JC, Kim MK, et al. (2003) Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest. Mol Cells 15: 356-360.
51. Kwack MH, Choi BY, Sung YK, (2006) Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells. Mol Cells 21: 224-228.
52. Liu B, Bell AW, Paranjpe S, Bowen WC, Khillan JS, et al. (2010) Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice. Hepatology 52: 1060-1067.
53. Ho M, Kim H, (2011) Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 47: 333-338.
54. Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, et al. (2010) Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs 21: 907-916.
55. Zhu AX GP, El-Khoueiry, AB, Abrams TA, Morikawa H, Ohtomo T, Philip PA, (2011) A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 29.